Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07893223). This is a study registration, not published results. Lead sponsor: Nutromics. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Biomarkers, Acute Kidney Injury, Sepsis. Primary outcome measures: Accuracy of Device-measured vancomycin ISF concentration vs. paired serum concentration , Up to 5 Days; Accuracy of Device-measured biomarker (creatinine, C-reactive protein, lactate) ISF concentration vs. paired serum concentration , Up to 5 days; Relationship between ISF analyte concentrations and clinical outcomes , Through 30 days after study completion; General performance characterisation of the Device , Up to 5 days. Brief summary: The goal of this observational study is to understand whether a wearable sensor (the Nutromics Sensor Device) can accurately measure drug and biomarker levels in the fluid just under the skin (interstitial fluid), instead of needing repeated blood draws, in adults admitted to hospital who are being treated with the antibiotic vancomycin or who are being monitored for signs of sepsis. The main questions it aims to answer are: * How closely do interstitial fluid levels of vancomycin match levels measured in the blood at the same time? * How closely do interstitial fluid levels of creatinine, C-reactive protein, and lactate (biomarkers linked to kidney function, inflammation, and infection severity) match levels measured in the blood? * Can the device pick up on early biomarker trends that signal a patient may be developing acute kidney injury? * How well does the device work overall, and does it perform consistently across different patients (by age, sex, ethnicity, body size, and health conditions) and over time? * Is the device safe to wear? There is no comparison group receiving a different treatment. This study looks at how well the device's readings line up with standard blood tests, not about testing a new treatment. Participants will: * Wear up to two small sensor patches on their upper arm during their hospital stay (up to 5 days), with each patch replaced every 48 hours * Have blood samples taken as part of their routine care so results can be compared * Have their medical records reviewed 30 days after finishing the study to check on their health outcomes